1229457-91-3

Basic information

• Product Name: 1-(2,6-dichloro-3-fluorophenyl)ethyl methanesulfonate
• Synonyms: 1-(2,6-dichloro-3-fluorophenyl)ethyl methanesulfonate
• CAS NO: 1229457-91-3
• Molecular Weight: 287.139
• Mol File: 1229457-91-3.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 1-(2,6-dichloro-3-fluorophenyl)ethyl methanesulfonate(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2,6-dichloro-3-fluorophenyl)ethyl methanesulfonate(1229457-91-3)
• EPA Substance Registry System: 1-(2,6-dichloro-3-fluorophenyl)ethyl methanesulfonate(1229457-91-3)

Safety Data

• Hazardous Substances Data: 1229457-91-3(Hazardous Substances Data)

Upstream product

• 756520-66-8 1-(2,6-dichloro-3-fluorophenyl)ethanol 
• 124-63-0 methanesulfonyl chloride 
• 290835-85-7 2',6'-dichloro-3'-fluoroacetophenone 

Downstream Products

• 1229457-92-4 6-bromo-1-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-1H-pyrrolo[3,2-b]pyridine 
• 1394930-38-1 6-bromo-3-[1-(2,6-dichloro-3-fluorophenyl)ethyl]-3H,4H-pyrido[2,3-d]pyrimidin-4-one 
• 877397-71-2 (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethyoxyl)-2-aminopyridine 
• 756520-67-9 (±)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-2-amine 
• 756521-08-1 (±)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-2-nitropyridine 

Relevant articles and documents

Discovery of 2-aminopyridines bearing a pyridone moiety as potent ALK inhibitors to overcome the crizotinib-resistant mutants

Despite the initial benefit demonstrated in clinical setting with ALK inhibitors, the challenging resistant mutants (F1174L, L1196M and G1202R) invariably developed. In this work, a series of 2-aminopyridine derivatives were designed and synthesized by C-5 position incorporation of a 2-pyridone moiety and bioisosteric replacement of the C-3 position linkers. Optimization of the 2-aminopyridine derivatives led to the identification of hit 18d displaying a significant growth inhibition against a variety of ALK-addicted cancer cells. Especially in the case of ALK-positive Karpas-299 cell, 18d exhibited excellent anti-proliferative potency with an IC50 value of about 40 nM. Moreover, 18d demonstrated encouraging activities against wild-type ALK (19 nM), ROS1 (2.3 nM) as well as challenging crizotinib-resistant ALKL1196M and ALKG1202R mutants with IC50 values of 45 nM and 22 nM, respectively. Additionally flow cytometric analysis indicates that 18d inhibited Karpas-299 cell viability via G1 phase arrest. Taken together, this work provided a promising ALK inhibitor to circumvent the clinical crizotinib-resistant mutants.

Method for preparing Crizotinib chiral intermediate

The invention relates to a method for preparing a Crizotinib chiral intermediate, which belongs to the field of medicine synthesis. The preparation method of the intermediate (1) is characterized in that chiral organic acidity is taken as a resolving agen

Synthesis and biological evaluation of 2-amino-5-aryl-3-benzylthiopyridine scaffold based potent c-Met inhibitors

A series of 2-amino-N-benzylpyridine-3-carboxnamides, 2-amino-N- benzylpyridine-3-sulfonamides and 2-amino-3-benzylthiopyridines against c-Met were designed by means of bioisosteric replacement and docking analysis. Optimization of the 2-amino-3-benzylthiopyridine scaffold led to the identification of compound (R)-10b displaying c-Met inhibition with an IC 50 up to 7.7 nM. In the cytotoxic evaluation, compound (R)-10b effectively inhibited the proliferation of c-Met addictive human cancer cell lines (IC50 from 0.19 to 0.71 μM) and c-Met activation-mediated cell metastasis. At a dose of 100 mg/Kg, (R)-10b evidently inhibited tumor growth (45%) in NIH-3T3/TPR-Met xenograft model. Of note, (R)-10b could overcome c-Met-activation mediated gefitinib-resistance, which indicated its potential use for drug combination. Taken together, 2-amino-3-benzylthiopyridine scaffold was first disclosed and exhibited promising pharmacological profiles against c-Met, which left room for further exploration.